Skip to main content

Table 3 Univariable and multivariable analyses for Overall Survival (OS), Progression Free Survival (PFS) and Locoregional Recurrence-Free Survival (LRFS)

From: Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

 

Locoregional Recurrence Free Survival

Progression Free Survival

Overall Survival

 

Unadjusted HR

Adjusted HR

Unadjusted HR

Adjusted HR

Unadjusted HR

Adjusted HR

15–18 aged

(ref: >18years)

0.80 (0.63–1.01); 0.065

0.86 (0.67–1.10); 0.226

1.00 (0.86–1.17); 0.968

0.85 (0.72–1.01); 0.063

0.98 (0.78–1.24); 0.862

0.76 (0.60–0.98); 0.033

Gender male

(ref: female)

0.87 (0.72–1.06); 0.169

0.91 (0.74–1.11); 0.354

1.16 (1.01–1.32); 0.034

1.05 (0.91–1.22); 0.476

1.33 (1.08–1.63); 0.007

1.20 (0.96–1.49); 0.110

de novo metastatic disease

(ref: no)

---

---

2.59 (2.18–3.07); <0.001

2.20 (1.83–2.64); <0.001

3.75 (2.99–4.68); <0.001

2.90 (2.29–3.67); <0.001

Tumor size ≤ 10 cm or not documented (ref:>10 cm)

1.14 (0.88–1.46); 0.292

0.94 (0.72–1.22); 0.632

2.59 (2.18–3.07); <0.001

0.79 (0.67–0.93); 0.006

0.66 (0.53–0.83); <0.001

0.82 (0.64–1.04); 0.102

Lower limb

(ref: other)

0.67 (0.540.82); <0.001

0.73 (0.59–0.92); 0.008

0.72 (0.63–0.83); <0.001

0.76 (0.66–0.89); <0.001

0.59 (0.48–0.74); <0.001

0.60 (0.47–0.76); <0.001

Site of tumor

Bone

(ref: Soft tissue)

0.97 (0.79–1.17); 0.736

1.43 (1.13–1.81); 0.003

1.05 (0.92–1.20); 0.503

1.07 (0.91–1.25); 0.417

0.98 (0.80–1.20); 0.842

0.87 (0.69–1.11); 0.259

Tumor grade

Grade 3

(ref: grades 1–2)

1.04 (0.75–1.44); 0.823

1.02 (0.73–1.43); 0.910

2.69 (2.09–3.46); <0.001

2.20 (1.76–2.98); <0.001

3.85 (2.51–5.88); <0.001

3.27 (2.11–5.05); <0.001

Ungraded tumor

(ref: grades 1–2)

1.99 (1.44–2.77); <0.001

1.82 (1.31–2.53); <0.001

1.97 (1.49–2.59); <0.001

1.88 (1.42–2.49); <0.001

1.05 (0.63–1.76); 0.847

1.10 (0.65–1.86); 0.711

AYA in RSC

(ref: AYA in non-RSC)

0.58 (0.47;0.70); <0.001

0.58 (0.46–0.73); <0.001

0.86 (0.76–0.99); 0.035

0.83 (0.71–0.97); 0.021

1.12 (0.91–1.39); 0.269

1.10 (0.87–1.40); 0.392

  1. Multivariable regression analyses for OS (n = 2009), PFS (n = 1956) and LRFS (n = 2046)
  2. HR Hazard ratio, 95% Confidence Interval, p value; RSC Reference Sarcoma Centers, ref reference value